Pfizer Inc. (NYSE:PFE) Shares Purchased by Sompo Asset Management Co. Ltd.

Sompo Asset Management Co. Ltd. increased its stake in Pfizer Inc. (NYSE:PFE) by 15.1% in the second quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 22,470 shares of the biopharmaceutical company’s stock after purchasing an additional 2,950 shares during the period. Sompo Asset Management Co. Ltd.’s holdings in Pfizer were worth $629,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors also recently bought and sold shares of PFE. Gilbert & Cook Inc. grew its position in Pfizer by 3.8% during the 4th quarter. Gilbert & Cook Inc. now owns 25,651 shares of the biopharmaceutical company’s stock worth $738,000 after purchasing an additional 945 shares during the period. Gryphon Financial Partners LLC grew its stake in shares of Pfizer by 43.7% during the 4th quarter. Gryphon Financial Partners LLC now owns 26,942 shares of the biopharmaceutical company’s stock worth $861,000 after purchasing an additional 8,194 shares during the period. Quest Partners LLC purchased a new position in shares of Pfizer during the 4th quarter valued at approximately $186,000. SageView Advisory Group LLC lifted its stake in shares of Pfizer by 2.2% in the 4th quarter. SageView Advisory Group LLC now owns 45,186 shares of the biopharmaceutical company’s stock valued at $1,221,000 after purchasing an additional 973 shares during the period. Finally, TCW Group Inc. raised its holdings in Pfizer by 82.7% in the 4th quarter. TCW Group Inc. now owns 205,376 shares of the biopharmaceutical company’s stock worth $5,913,000 after purchasing an additional 92,970 shares during the period. Hedge funds and other institutional investors own 68.36% of the company’s stock.

Pfizer Price Performance

Shares of PFE opened at $29.42 on Friday. The company has a debt-to-equity ratio of 0.65, a current ratio of 0.86 and a quick ratio of 0.60. The stock has a market cap of $166.71 billion, a PE ratio of -490.25, a P/E/G ratio of 1.05 and a beta of 0.68. The firm has a 50-day simple moving average of $29.36 and a two-hundred day simple moving average of $28.24. Pfizer Inc. has a 1-year low of $25.20 and a 1-year high of $34.11.

Pfizer (NYSE:PFE) last released its quarterly earnings results on Tuesday, July 30th. The biopharmaceutical company reported $0.60 EPS for the quarter, topping the consensus estimate of $0.46 by $0.14. The business had revenue of $13.28 billion during the quarter, compared to analyst estimates of $12.96 billion. Pfizer had a positive return on equity of 8.42% and a negative net margin of 4.66%. The company’s quarterly revenue was up 2.1% on a year-over-year basis. During the same period last year, the business posted $0.67 earnings per share. As a group, analysts forecast that Pfizer Inc. will post 2.66 EPS for the current year.

Pfizer Announces Dividend

The firm also recently declared a quarterly dividend, which was paid on Tuesday, September 3rd. Stockholders of record on Friday, July 26th were given a dividend of $0.42 per share. The ex-dividend date was Friday, July 26th. This represents a $1.68 annualized dividend and a dividend yield of 5.71%. Pfizer’s dividend payout ratio is presently -2,799.53%.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on the stock. Cantor Fitzgerald reissued an “overweight” rating and issued a $45.00 price target on shares of Pfizer in a research note on Monday, September 16th. Barclays boosted their price target on shares of Pfizer from $30.00 to $32.00 and gave the stock an “equal weight” rating in a research report on Wednesday, July 31st. Wells Fargo & Company upped their price target on Pfizer from $28.00 to $30.00 and gave the company an “equal weight” rating in a research report on Wednesday, July 31st. UBS Group boosted their price objective on Pfizer from $30.00 to $31.00 and gave the stock a “neutral” rating in a research note on Wednesday, July 31st. Finally, StockNews.com upgraded Pfizer from a “hold” rating to a “buy” rating in a report on Thursday, August 1st. Eight investment analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, Pfizer presently has an average rating of “Moderate Buy” and a consensus price target of $34.54.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.